A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection by Ruggiero, T et al.
A(H1N1)pdm09 hemagglutinin D222G and D222N variants
are frequently harbored by patients requiring
extracorporeal membrane oxygenation and advanced
respiratory assistance for severe A(H1N1)pdm09 infection
Tina Ruggiero,a Francesco De Rosa,b* Francesco Cerutti,a Nicole Pagani,b Tiziano Allice,a Maria L. Stella,b
Maria G. Milia,a Andrea Calcagno,b Elisa Burdino,a Gabriella Gregori,a Rosario Urbino,c Giovanni Di
Perri,b Marco V. Ranieri,c Valeria Ghisettia*
aDepartment of Infectious Diseases, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy. bDepartment of Infectious
Diseases, Amedeo di Savoia Hospital, University of Turin, Turin, Italy. cDepartment of Anaesthesia and Intensive Care Medicine, San Giovanni
Battista-Molinette Hospital, University of Turin, Turin, Italy.
Correspondence: Valeria Ghisetti, MD, Department of Infectious Diseases, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Corso
Svizzera 164, Torino 10149, Italy. E-mail: valeria.ghisetti@gmail.com
*These authors equally contributed to the work.
Accepted 2 July 2013. Published Online 09 August 2013.
Background In patients with A(H1N1)pdm09 infection, severe
lung involvement requiring admission to intensive care units (ICU)
has been reported. Mutations at the hemagglutinin (HA) receptor
binding site (RBS) have been associated with increased virulence
and disease severity, representing a potential marker of critical
illness.
Objectives To assess the contribution of HA-RBS variability in
critically ill patients, A(H1N1)pdm09 virus from adult patients with
severe infection admitted to ICU for extracorporeal membrane
oxygenation support (ECMO) during influenza season 2009–2011 in
Piemonte (42 million inhabitants), northwestern Italy, was studied.
Patients and methods We retrospectively analyzed HA-RBS
polymorphisms in ICU patients and compared with those from
randomly selected inpatients with mild A(H1N1)pdm09 disease and
outpatients with influenza from the local surveillance program.
Results By HA-RBS direct sequencing of respiratory specimens,
D222G and D222N viral variants were identified in a higher
proportion in ICU patients (n = 8/24, 333%) than in patients with
mild disease (n = 2/34, 6%) or in outpatients (n = 0/44) (Fisher’s
exact test P < 00001; OR 385; CI 95% 4494–3299). Eleven ICU
patients died (42%), three of them carrying the D222G variant,
which was associated with RBS mutation S183P in two. D222G and
D222N mutants were identified in upper and lower respiratory
samples.
Conclusions A(H1N1)pdm09 HA substitutions D222G and D22
2N were harbored in a significantly higher proportion by patients
with acute respiratory distress for A(H1N1)pdm09 severe infection
requiring ICU admission and ECMO. These data emphasize the
importance of monitoring viral evolution for understanding virus–
host adaptation aimed at the surveillance of strain circulation and
the study of viral correlates of disease severity.
Keywords A(H1N1)pdm09 virus, extracorporeal membrane oxy-
genation and influenza, hemagglutinin D222G and D222N variants.
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Background
Although the majority of A(H1N1)pdm09 infections present
as mild or self-limited disease, severe lung involvement in
patients requiring admission to intensive care units (ICU)
has been responsible for high morbidity and mortality, and
efforts have been made to identify A(H1N1)pdm09 correlates
of severe disease.1–3
Changes in viral receptor binding affinity at the binding
site (RBS) play a critical role in influenza virus tropism and
virulence. Studies on viral correlates of disease severity
identified that amino acid mutations in the viral hemag-
glutinin (HA) receptor binding domain could be potentially
responsible for influenza outbreaks due to a switch in the
receptor binding tropism with a higher affinity for respi-
ratory cells in the lower than in the upper respiratory tract,
DOI:10.1111/irv.12146
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leading to a more aggressive disease.4,5 Specific mutations
in the A(H1N1)pdm09 HA occurred during virus–host
adaptation have been shown to enhance viral binding to a-
2,3 sialic acid receptors located in the lower respiratory
tract.
Hemagglutinin receptor binding site sequence corre-
sponding to codons 170 to 230 including positions 190
(helix), 220 (loop), and 130 (loop) is considered a major
factor in determining HA binding in all A(H1N1)pdm09
strains.6,7 This sequence is also involved in antigen recog-
nition by the host, and mutations at this point could alter
the antibody reactivity as well as the ability of the virus to
infect cells. A(H1N1)pdm09 HA-RBS displays a considerably
higher hydrophilic characteristic than the HA-RBS from
other strains, probably due to some key amino acid
substitutions mainly located between position 223 and 225
involved in binding strength and affecting surrounding
residues. Most represented amino acid substitutions in the
HA-RBS within A(H1N1)pdm09 clades have been recently
described with a frequency of 35% at position 172, 53% at
183, 175% at 185, 316% at 205, 32% at 216, and 145% at
222.8 Important polymorphisms at the HA-RBS, such as
G155E, S183P and D222G, have been identified in animal
models and then confirmed in humans to increase viral
affinity for the a-2,3 receptors and are thus possibly
associated with involvement and infection of the lower
respiratory tract.6,9
During the 2009 A(H1N1)pdm09 outbreak, substitution
of aspartic acid with glycine at position 222 (D222G) of HA 1
subunit of A(H1N1)pdm09 has been associated with
increased virulence, disease severity, and fatal outcomes.
This substitution was first observed in severe clinical cases of
A(H1N1)pdm09 infection in Norway and then confirmed in
fatal and severe outcomes of A(H1N1)pdm09 infection in
Scotland, Spain, and Italy.10–14 Important data on the
evolutionary dynamics and temporal diversification of
D222G strains have been reported also for the recent 2010–
2011 season.7
To assess the contribution of HA-RBS variability in A
(H1N1)pdm09 disease severity, we retrospectively investi-
gated HA-RBS polymorphisms in critically ill adult
patients requiring ICU admission for A(H1N1)pdm09
infection during the two influenza seasons 2009–2010
and 2010–2011. Virological data from patients requiring
ECMO were compared with those from randomly selected
inpatients with mild A(H1N1)pdm09 disease and outpa-
tients reported by sentinel practitioners from the local
influenza surveillance program within the National Sur-
veillance Plan. Primary objective was to identify specific A
(H1N1)pdm09 HA genetic correlates of disease severity
and fatal outcome in order to improve the understanding
of the clinical course of A(H1N1)pdm09 infection in
critically ill patients.
Patients and methods
Study groups
During the two influenza seasons 2009–2010 and 2010–2011,
respiratory samples for the detection of influenza viruses
were processed at the Laboratory of Microbiology and
Virology of the Department of Infectious Diseases, Amedeo
di Savoia Hospital in Turin, which received 3986 respiratory
samples covering a geographic area of 42 million inhabit-
ants. Pandemic A(H1N1)pdm09 virus was identified in 1229
specimens (30%). Sixty-seven adult patients (55%) with A
(H1N1)pdm09 severe complications required ICU admis-
sion in the two seasons; 26 of them (388%) were referred to
the regional reference center for ECMO (ICU-ECMO
group). Randomly selected A(H1N1)pdm09-infected inpa-
tients (n = 34) hospitalized with mild disease and outpa-
tients reported by sentinel practitioners from the local
influenza surveillance program (n = 44) served as control
groups.
A(H1N1)pdm09 molecular detection and HA
polymorphism analysis
Respiratory specimens were processed for A(H1N1)pdm09
detection in a two-step procedure: a nucleic acid-based
screening tests for type A and B influenza viruses by a
commercial real-time PCR (Seegene Inc., Seoul, South Korea)
followed by A(H1N1)pdm09 subtyping with a one-step real-
time reverse transcription (RT) PCR. A modified WHO-CDC
protocol (April 28, 2009, www.cdc.gov)15 was applied for A
(H1N1)pdm09 detection with specific MGB probes (Applied
Biosystems, Foster city, CA, USA) and the combined identi-
fication of three viral genes:matrix for generic flu type A, swine
flu type A nucleoprotein, and A(H1N1)pdm09 HA. Amino
acid polymorphisms in A(H1N1)pdm09 HA-RBS were deter-
mined by directHA sequencing from clinical specimens.6,13 An
internal HA fragment of 475 bp (from 446nt to 921nt
according to A/California/07/2009 strain) was sequenced with
the BigDye Terminator Cycle-Sequencing Reaction on the ABI
Prism 3130 XL DNA sequencer (Applied Biosystems). We
analyzed HA-RBS sequence corresponding to codons 170 to
230 including positions 190 (helix) and 220 (loop elements),
based on reference data showing that these elements are major
factors in determining HA binding in all H1N1/HA strains.6,13
Sequences were assembled using SeqScape 2.0 (Applied
Biosystems) and aligned with ClustalW using the A/Califor-
nia/07/2009, Acc. N. FJ966974 as reference strain. For phylo-
genetic analysis, the data set of our sequences was compared to
sequences from England, France, Germany, and Norway, for a
total of 455 sequences. The phylogenetic tree was constructed
using the BioNJ method implemented in the PhyML software,
with a bootstrap equal to 1000.16–18 Amino acid substitutions
were given for internal nodes. To study the frequency of viral
polymorphisms, a data set of 2704 A(H1N1)pdm09 sequences
Ruggiero et al.
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from Europe covering 2 years (May 2009–May 2011) obtained
from the NCBI Influenza Virus Resources (http://www.ncbi.
nlm.nih.gov/genomes/FLU/FLU.html) was constructed. A
(H1N1)pdm09 partial hemagglutinin sequences (373 bp,
from 441nt to 863nt according to A/California/07/2009 strain)
were aligned, and specific A(H1N1)pdm09 polymorphisms
were analyzed with R statistical software and the package
SeqinR, then referred to the entire data set.19,20
Statistical analysis
Analysis of mutation frequencies within different groups of
patients and control groups was performed using the chi-
square test (with Fisher’s exact test where appropriate) and
considered to be significant at a level of 005. Statistical
analysis was performed using PASW Statistics 18.0.2 (SPSS
Inc, Chicago, IL, USA).
Results
Detailed characteristics of the 26 ICU-ECMO patients
admitted during the two influenza seasons from November
2, 2009, to March 31, 2010 (16 patients) and from January 14
to March 31, 2011 (10 patients), are given in Table 1. Median
time from hospitalization to ICU admission was 2 days
(average: 48, 95% CI: 25–71). Median APACHE score for
all patients was 185 and comorbidities were present in the
majority of them (22 patients, 846%), including obesity with
a body mass index >30 (Kg/m2) in 10 patients. All but two
patients had fever, and leukocyte count was normal in 17
patients and >103 WBC/ll in 9 of them. At ICU admission,
X-ray or CT scan revealed lung involvement in 18 patients
(69%) and acute respiratory distress syndrome (ARDS) in 3
(115%). All patients were sampled for A(H1N1)pdm09 24–
72 hours after hospital admission prior to ICU transfer for
ECMO support. After A(H1N1)pdm09 detection, they
received antiviral treatment within 24–48 hours (oseltamivir,
standard dosage 75 mg BID increased to 150 mg BID in two
patients), and average duration of oseltamivir treatment was
8 days (5).
Clinical and microbiological evidence of bacterial or
fungal co-infection was found in 14 patients (53%)
(Table 2), and six of them died due to septic shock and
multiorgan failure. Four patients suffered from extensive
pneumonia due to Aspergillus fumigatus and two died.
Eleven of 24 patients died (42%): seven within the first
15 days and four within 45 days from ICU admission.
Median length of ICU staying was 10 days for non-survivors
and 19 days for survivors. Primary reported causes of death
were multiorgan failure (nine patients), septic shock (eight
patients, six with evident bacterial co-infection) and cardiac
arrest (two patients). Comorbidity was the only significant
variable that correlated with survival rates (Fisher’s exact test
P = 15, OR: 00667, 95% CI: 0006667–06657).
One-hundred and ten respiratory samples from 60 inpa-
tients and 44 outpatients were included in the study. Nucleic
acid sequencing of A(H1N1)pdm09 HA was performed
directly from respiratory samples [42 pharyngeal and 57
nasal swabs, 11 bronchoalveolar lavages (BAL)]. HA nucle-
otide sequence identity with the reference A/California/07/
2009 ranged from 975% to 991%, with a maximum of 14
amino acid changes. Analysis of HA mutation revealed
position 222 as the most variable site. Polymorphisms at this
position were observed in 30 patients (288%); substitution
D222G was found in 8 (77%), D222N in 2 (19%), and
D222E in 20 (192%). D222G and D222N polymorphisms
were detected in 8 ICU-ECMO patients, in only two
inpatients with mild disease, and in none of the outpatients
from the local influenza surveillance system. Statistical
analysis showed that mutations D222G and D222N were
harbored in a significantly higher proportion (333%) by
patients with A(H1N1)pdm09 severe disease requiring ICU
admission for advanced respiratory supply and ECMO
(Fisher’s exact test P < 00001; OR 385; 95%CI: 4494–
3299) than by inpatients with mild disease (59%) or
outpatients (0%) (Table 3). Moreover, the presence of
D222G or D222N correlated with an older age (mean
age  SD for D222G or N carriers: 467  7 versus
312 + 24 in non-carriers, P = 0002). In ICU-ECMO
patients, D222G and D222N mutants were identified in 4
BALs (36%) and in 4 (20%) upper respiratory specimens. In
five ICU-ECMO patients, paired upper and lower respiratory
samples were available for matched analysis, showing a
perfect match of viral strains at the upper and lower
respiratory level (Table 1, patient ID nos 2, 3, 5, 8, and
18). Viral shedding from the lower respiratory tract as
evaluated on consecutive BALs ranged from 14 to 26 days
(average 194 days). In ICU-ECMO patients, dichotomous
variables (age > 50 years, BMI > 25, invasive ventilation at
admission, bacterial/fungal co-infection, and survival) were
tested for association with polymorphisms at position 222,
but no significant association was found at univariate
analysis (chi-square and Fisher’s exact test).
Hemagglutinin polymorphisms at position different from
D222 were analyzed across the study groups. The following
polymorphisms were found: S185T (n = 14 patients, 2 ICU-
ECMO, 10 inpatients, and two outpatients), A186T (n = 3
patients, 1 ICU-ECMO, and 2 outpatients), Q193H (n = 1
outpatient), A197T (n = 3, 1 ICU-ECMO and 2 inpatients),
R205K in combination with I216V (n = 23, 3 ICU-ECMO,
14 inpatient, and 6 outpatients), I216E (n = 1 inpatient),
K209T (n = 1 outpatient), M227K (n = 1 inpatient), and
P236Q (n = 1 inpatient). None of these polymorphisms was
significantly associated with ICU admission, disease severity
and fatal outcome. Substitution S183P was identified in 10
patients (two ICU-ECMO and eight inpatients with mild
disease), associated with D222G in 2 ICU-ECMO cirrhotic
D222G/N in A(H1N1)pdm09 patients requiring ECMO
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patients who died of sepsis and multiorgan failure following
A(H1N1)pdm09 infection (Table 1, patients ID nos 22 and
26). Genetic analysis showed that A(H1N1)pdm09 strains
from these patients belonged to a unique nosocomial cluster
(Figure 1).21 Substitution D222E was present in 20 subjects
from all the study groups, but only in the season 2009–2010,
while it disappeared in the following year. Considering all
HA-RBS polymorphisms, ICU-ECMO patients and inpa-
tients hospitalized with mild disease showed a significant
higher number of mutations than outpatients (833% and
853% versus 590%, v2 829, P = 0004).
The phylogenetic analysis (Figure 1) of A(H1N1)pdm09
sequences from our series in comparison with other 353
European strains circulating from the year 2009–2011
showed the absence of distinct genetic D222G and D222N
clusters in the two seasons apart from two very small clusters
consisting, the first, of five strains (2 of them from the ICU-
ECMO series, Table 1, patients ID nos 1 and 4) and another
one (ICU-ECMO patients ID nos 22 and 26). According to
major RBS amino acid substitutions, the following A(H1N1)
pdm09 clades were identified: S185T (including 38
sequences: 83%), R205K + I216V (63 sequences: 138%),
D222E (67 sequences: 147%), and S183P (36 sequences:
79%).
The study of the circulation of A(H1N1)pdm09 major
polymorphisms on 2704 European sequences from European
strains circulating from the year 2009–2011 showed for
specific hot spots the following frequency: D222G, 28%;
D222N, 08%; D222E, 16%; S183P, 22%, S185T, 102%,
R205K, 55%; I216V, 48% (R205K + I216V: 55%) and
A197T, 17%.
A(H1N1)pdm09 HA nucleotide sequences from
ICU-ECMO patients were submitted to the NCBI GenBank
with accession numbers CY098210–CY098218 and CY09
8275–CY098290.
Discussion
Worldwide surveillance studies on pandemic influenza have
reported that A(H1N1)pdm09 infection is associated with a
higher risk of severe disease, hospitalization and ICU
admission than seasonal influenza, especially if there is a
delay in antiviral treatment.22–25 Herein, we report the
clinical outcome and virological findings of patients admit-
ted to ICU for advanced respiratory assistance and ECMO
during the influenza seasons 2009–2010 and 2010–2011, in
Piemonte, northwestern Italy (42 million inhabitants). In
that period, 55% of patients with A(H1N1)pdm09 infection
required ICU admission for severe complication and 388%
of them were referred to the regional reference center for
Table 2. Co-infections in patients with A(H1N1)pdm09 infection
who required advanced respiratory assistance and ECMO. See Table 1
for patient reference
Patient
ID
Site of bacteria
/fungi isolation
Microbial
agent
1 BAS P. aeruginosa *
3 BAL A. fumigatus
5 BAS + blood A. baumannii*,
E. coli
6 BAS + blood A. baumannii*,
S. marcescens
7 BAS S. maltophilia,
A. baumanni,
Klebsiella spp**
8 BAS A. baumannii
10 Blood E. faecalis
17 BAL A. fumigatus,
Pseudomonas spp
18 BAL A. fumigates
19 Blood K. pneumoniae**
20 BAL S. maltophilia*
22 Sputum + skin lesion K. pneumoniae**,
A. baumanii,
E. cloacae*
25 BAS + blood E. cloacae, E. cloacae
26 BAL + lung at autopsy A. fumigatus
BAS, bronchoaspirate; BAL, bronchoalveolar lavage.
*Multidrug resistant strain.
**Multidrug resistant carbapenemase production strain (KPC).
Table 3. Amino acid at HA position 222 of A(H1N1)pdm09 virus in
ICU-ECMO and other study groups. Percentage (in parenthesis)
calculated for each group with respect to the total number of patients
in that group
Amino acid
at HA
position 222
Total
(N = 102)
ICU-ECMO
Patients
(N = 24)
Inpatients
with mild
disease
(N = 34)
Surveillance
group **
(N = 44)
D222
(wild type)
72 10
(416%)
32
(94%)
30
(681%)
D222E 20 6
(25%)
0
(0%)
14
(318%)
D222N 2 1*
(4%)
1*
(3%)
0*
(0%)
D222G 8 7*
(29%)
1*
(3%)
0*
(0%)
ICU-ECMO, intensive care unit-extracorporeal membrane
oxygenation.
*Rate of ICU-ECMO patients carrying the D222G and D222N
substitution significantly higher than the other groups (Fisher’s exact
test P < 00001; OR 385; 95% CI: 4494–3299).
**Forty-four not-hospitalized individuals with mild A(H1N1)pdm09
influenza from the local surveillance program.
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critical illness requiring ECMO support. These patients
presented a rapid worsening of A(H1N1)pdm09 infection
shortly after hospital admission with bilateral or single-lung
pneumonia and ARDS that required advanced respiratory
support including ECMO. A significant proportion of them
(42%) died, and the majority of death occurred within the
first 7 days after ICU admission.
As the natural tendency of influenza viruses to acquire
point mutations at different genomic positions is very well
known and changes at the RBS can alter antigenic properties
and viral pathogenicity, we evaluated HA genetic correlates
of disease severity in these critically ill patients and compared
virological data with those from the control group.
Recent data have pointed out that HA-RBS sequence
corresponding to codons 170 to 230 is a major factor in
determining HA binding and antigen recognition.6,13 Most
represented hot spots for amino acid substitutions within A
(H1N1)pdm09 clades are positions 183, 185, 205, 216, and
222.8 Key amino acid substitutions at the RBS can possibly
affect surrounding residues and alter antibody reactivity as
well as the ability of the virus to infect cells. Of all mutations,
substitutions at position 222 (either as G or N) have been
detected only in patients with severe disease. Data from the A
(H1N1)pdm09 worldwide surveillance have reported that
substitutions D222G and D222N at HA-RBS have been
detected in a significant proportion of severe cases: 63 % in a
study from Spain, 147% from Norway, 87% from Finland,
83% from France, 69% from West Scotland, 41 % and
63% from two studies in Hong Kong, 30% and 58% from
Italy, 154% from India and 217% from Greece.5,10,13,14,26–30
Our study highlighted that the highest number of HA
polymorphisms were found at position 222 in ICU-ECMO
patients compared with control groups. D222G and D222N
RBS variants were detected in 333% of patients with A
(H1N1)pdm09 severe infection requiring advanced respira-
tory support and ECMO, while these mutations were present
at a significantly lower proportion (59%) in inpatients who
did not require ECMO and were absent in viral isolates from
outpatients of the local surveillance program.31,32 D222N
substitution was less frequent than D222G, as suggested by
the very low circulation of this variant (08%) among the
European A(H1N1)pdm09 sequences of the same period that
we analyzed. On the contrary, the highly circulating variant
D222E (16%) was detected in both severe and mild cases,
confirming that it was not associated with A(H1N1)pdm09
disease severity.33 Moreover, we observed D222E circulating
strains only in the season 2009–2010 and not in the following
one.
The increased virulence of D222G and D222N strains is
postulated due to an enhanced binding affinity for the a-2,3
sialic acid receptor present at higher density on cell surface in
the lower respiratory tract rather than for the a-2,6 sialic acid
receptor located at higher density on upper respiratory tract
cells.34,35 Substitution D222G, which is located in the
receptor binding cavity at the Ca antigenic site of HA,
changes the properties of the RBS from acid and polar to
neutral and non-polar, and experimental data have shown
that this mutation causes a shift to a dual a-2,3/a-2,6-linkage
specificity, enabling the mutated HA to bind to both upper
and lower respiratory receptors, supporting the hypothesis
that viruses with dual receptor binding specificity can
replicate at high level in lung tissue producing a more
aggressive disease.36 Therefore, the complexity of A(H1N1)
pdm09 virus–host interaction and adaptation is modulated
by changes at the HA binding site.
In agreement with published data, we confirmed the
higher proportion of D222G and D222N viral strains from
patients with A(H1N1)pdm09 severe disease, but we addi-
tionally showed that the requirement of ECMO as advanced
respiratory support was significantly associated with infec-
tion due to viruses carrying these HA substitutions at the
RBS. Furthermore, we demonstrated the presence of D222G
and D222N mutants in both upper and lower respiratory
samples from critically ill patients.
In agreement with the rare circulation of these mutants
during periods of high spread of influenza virus as shown by
ours and other studies,8 phylogenetic analysis identified only
two very small clusters of D222G viruses, both including
ICU-ECMO patients from our series, one of the two clusters
due to the nosocomial spread of D222G variant.21 Therefore,
the high frequency of D222G strains in critically ill patients
could be explained by the selection of these mutants in the
Figure 1. Phylogenetic tree of partial A(H1N1)pdm09 HA. Phylogenetic analysis of influenza A(H1N1)pdm09 partial hemagglutinin gene (373 bp, from
441nt to 863nt according to A/California/07/2009 strain) of 455 sequences. The tree was constructed by the BioNJ method implemented in the PhyML
software, with bootstrap equal to 1000. Amino acid substitutions are given for internal nodes. Bootstrap values were omitted for tree readability.
Sequence from outpatient ID24 was excluded from the tree reconstruction, because the sequence was too short. Main substitutions were reported on the
branch of the respective clade. Details of collapsed sequences labeled with A and B are given magnified, because they form two important clades
corresponding to polymorphism S185T and A197T (clade A), R205K + I216V (clade B). Collapsed clades are composed as follows: clade C (including
D222E polymorphism): four strains from Italy, two from France, two from Germany, two from Norway, and 5 from England; clade D (corresponding to
D222 wild type), from our series: 11 outpatients, 3 ICU-ECMO (ID5, ID11, ID20, who died), then 31 strains from Italy, two from France, 10 from Germany,
nine from Norway, and 18 from England; clade E (corresponding to D222 wild type including reference strain A/California/07/2009), from our series: two
outpatients, then 12 strains from Italy, four from France, five from Germany, two from Norway, and five from England; clade F (corresponding to D222
wild type): 1 from France, 3 from Norway, and 1 from England. †dead patients.
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context of disease severity at the individual level instead of
viral spreading.5,37
Among other HA-RBS substitutions associated with severe
disease, themost significant was themutation S183P, typical of
all 1918 H1N1 viruses.6–39 We identified S183P mutants only
in 2011 circulating strains from 10 inpatients, two of them
belonging to the ICU-ECMO series. In the two ICU-ECMO
patients who died of A(H1N1)pdm09 complications, S183P
was associated with D222G, whereas in inpatients with mild
disease, S183P was alone and no outpatients from the local
influenza surveillance system carried thismutation. Analysis of
European A(H1N1)pdm09 strains identified only another
virus from the year 2010 carrying the double mutations S183P
and D222G from a severely infected patient who died in
England (Figure 1, Acc. JX625910 GenBank notes). Therefore,
the rare combination of the double mutant S183P and D222G
(frequency: 01%) probably characterizes a more virulent
strain associated with disease severity and case fatality.
We recognize that important limitations of our study were
the lack of lower respiratory samples from all patients (BALs
were available for only 108% of patients) as well as the lack
of matched upper and lower respiratory samples (available
for only five patients, none of them carrying mutation
D222G). Therefore, in our series the presence of D222G and
D222N mutations could be underestimated due to the
potential higher tropism of these variants for the lower
respiratory tract, even if there are recent data showing that
D222G and D222N variants can be found in samples from
the upper respiratory tract.40,41 Our underestimation could
also be due to the sensitivity of the technique applied for viral
typing, that is, population-based DNA sequencing that did
not allow to appreciate the composition of viral population
at a quasi-species level. A recent work outlined a much
higher detection rate of variants at position 22240 with a
highly sensitive ultra-deep pyrosequencing technology that
found the presence of G and N variants in >40% of patients
compared with <19% with the conventional population-
based DNA sequencing. Other studies have confirmed that
when ultra-deep pyrosequencing or clonal analysis are used
for strain identification, the proportion of upper respiratory
samples carrying D222 variants increases to levels similar to
those of the lower tract.5,42 Therefore, discrepancy between
the detection of D222G and D222N variants in upper and
lower respiratory tract must take into consideration the
different sensitivity of analytical methods for viral detection
and typing40,42 and that population-based DNA sequencing
is known to detect minor variants only if these represent a
proportion higher than 15–20% of the whole population. All
the above-mentioned studies showed a general agreement
that D222G and D222N variants can be detected only in
patients with severe disease.
Other limitations of our study are the lack of data on A
(H1N1)pdm09 viral load quantification in the upper and
lower respiratory tracts that did not allow information on
potential viral transmission and the paucity of information
on the time from the start of illness to sampling that is
supposed to play an important role as D222G and D222N
variants seem to be selected in the individual patient during
the time course of the infection.5,37 Comorbidities including
obesity and secondary infection were highly represented in
our ICU patients and had a major impact on patient survival,
thus complicating the role of D222G and D222N mutants in
determining disease severity.
In conclusion, the study of A(H1N1)pdm09 viral corre-
lates of disease severity, including the detection and mon-
itoring of HA variants at the RBS, emphasizes the importance
of continuous monitoring of A(H1N1)pdm09 evolution.
These data strongly support the epidemiological surveillance
of strain circulation for understanding virus–host interaction
and adaptation and viral correlates of disease severity.
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